Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
Yuko KanekoHideto KamedaKei IkedaTomonoti IshiiKosaku MurakamiHyota TakamatsuYoshiya TanakaTakayuki AbeTsutomu TakeuchiPublished in: Annals of the rheumatic diseases (2018)
The study suggests that tocilizumab is effective in adult-onset Still's disease, although the primary endpoint was not met and solid conclusion was not drawn.
Keyphrases
- phase iii
- placebo controlled
- double blind
- open label
- clinical trial
- phase ii
- study protocol
- rheumatoid arthritis
- phase ii study
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- randomized controlled trial
- tyrosine kinase
- disease activity
- radiation therapy
- combination therapy
- systemic lupus erythematosus
- replacement therapy